Recent Updates
Recently added Catalysts

rhBMP-2/CPM

Phase 1

Osteoarthritis | Small molecule | Musculoskeletal |Pfizer, Inc.|Last Updated: Oct 6, 2006

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment6
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00243295Study Evaluating rhMBP-2/CPM in Open Wedge OsteotomiesPHASE1 COMPLETED 6Nov 1, 2003Mar 1, 2005Oct 6, 2006 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Feasibility of injecting rhBMP-2/CPM using high tibial osteotomy as a surgical model for pharmacodynamic studies
Feasibility measures include
Injection of desired volume of rhBMP-2/CPM within the osteotomy defect
Ability to perform longitudinal radiographic absorptiometry of the defect in the presence of rhBMP-2/CPM.
Secondary Endpoints
Safety of administering different volumes of rhBMP-2/CPM in high tibial osteotomy defects. Safety assessed by evaluation of adverse events reported during the duration of the trial.
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeECT
Interventions
NameTypeDescription
rhBMP-2/CPMDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range45 Years — 70 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Male or female subjects 45 to 70 years of age * Within 96 hours prior to dosing, the subject underwent a successful open wedge tibial osteotomy to correct medial compartment OA of the knee. * Female subjects of childbearing potential must have a negative pregnancy test (hospit...

Unlock Eligibility Criteria